Tislelizumab plus AG regimen for long-term CR in 2 patients with metastatic BRCA-mutation pancreatic cancer: A case report
Year: 2024
Type: article
Study design: Case Report
Abstract: RATIONALE: An increased risk of pancreatic cancer (PC) is associated with breast cancer susceptibility gene (BRCA) mutations. Given limited therapies, there remains an urgent need to explore novel treatment strategies. PATIENT CONCERNS: We report 2 metastatic PC patients with BRCA mutations who initially did not respond to standard therapies. DIAGNOSES: Case 1 was diagnosed with metastatic PC harboring a BRCA1 mutation, and case 2 was diagnosed with metastatic PC harboring a BRCA2 mutation. INTERVENTIONS: Both patients received a modified AG regimen (albumin-bound paclitaxel plus oxaliplatin) combined with tislelizumab, followed by maintenance therapy with olaparib plus tislelizumab after 6 cycles. OUTCOMES: Both patients achieved complete response, with complete response lasting for 19 months in case 1 and 18 months in case 2. LESSONS: The combination of triple therapy followed by maintenance therapy shows promise as a potential treatment option for PC patients with BRCA mutations. Further clinical investigation is needed to confirm its efficacy and safety.
Source: Medicine
Authors: Feng Gao, Xue Xu, Chunhong Chen, Lili Lv
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,950
OpenAlex ID: W4405903134